Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IgG3 Fc

IgG3 Fc

Brief Information

Name:Immunoglobulin G
Target Synonym:Immunoglobulin G
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IG3-M5214 Mouse Mouse IgG3 Fc Protein, Tag Free (MALS verified)
IG3-H5200 Human Human IgG3 Fc Protein, Tag Free (MALS & SPR verified)
ACRO Quality

Part of Bioactivity data


Human FCGRT&B2M Heterodimer Protein, His Tag (Cat. No. FCN-H52W7) captured on CM5 Chip via anti-His antibody can bind Human IgG3 Fc, Tag Free (Cat. No. IG3-H5200) with an affinity constant of 2.82 μM as determined in SPR assay (Biacore 8K) (QC tested).

IgG3 Fc MALS images

The purity of Mouse IgG3 Fc Protein, Tag Free (Cat. No. IG3-M5214) is more than 90% and the molecular weight of this protein is around 60-70 kDa verified by SEC-MALS.

Synonym Name

Ig gamma-3 chain C region,IgG, IgG3


Immunoglobulin G3 (IgG3) is a member of many immunoglobulin G developed and secreted by effective B cells. In wake of cutting by pepsin, IgG is divided into two F(ab)s with one antigen binding site and a high conserved Fc segment. The Fc segment bears a highly conserved N-glycosylation site. Ig gamma-3 chain C region (IgG3-Fc / IGHG3) contains two constant regions of IgG3 H chain (CH2, CH3).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Imlifidase Mac-1 Approved Hansamed Inc Idefirix EU Rejection of renal transplantation Hansa Biopharma Ab 2020-08-25 Rejection of renal transplantation; Kidney Diseases; Purpura, Thrombotic Thrombocytopenic; Rejection of organ transplantation; Renal Insufficiency, Chronic; Guillain-Barre Syndrome; Kidney Failure, Chronic Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AT-02 AT-02 Phase 2 Clinical Attralus Inc Immunoglobulin Light-chain Amyloidosis; Amyloidosis Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) Phase 1 Clinical University Of California San Diego Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message